New research from the Cleveland Clinic reveals that patients who stop using GLP-1 medications like Ozempic experience minimal weight regain, challenging previous concerns about rebound weight gain.
As millions of individuals turn to injectable GLP-1 medications such as Ozempic, Wegovy, and Zepbound for weight management, many are left wondering what occurs when they discontinue treatment. Previous clinical trials indicated a concerning “rebound” effect, where patients often regained a substantial portion of their lost weight shortly after stopping the medication. However, a recent study conducted by the Cleveland Clinic, published in the journal Diabetes, Obesity and Metabolism, presents a more optimistic view of the outcomes following the cessation of these injections.
The study analyzed nearly 8,000 adults in Ohio and Florida who had been using semaglutide or tirzepatide for a duration of three to twelve months before stopping. Unlike the tightly controlled environments of clinical trials, this research focused on “real-world” outcomes, where patients frequently switch between different medications. The findings revealed that, overall, patients did not experience significant weight regain within the year following the discontinuation of a GLP-1 medication.
Among those treated specifically for obesity, the average weight loss prior to stopping was 8.4%. Remarkably, one year later, these individuals had regained only an average of 0.5% of their lost weight. Dr. Hamlet Gasoyan, the lead author of the study, noted in a press release, “Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials.”
This observation suggests that the rebound weight gain seen in clinical trials may stem from patients being left without alternative support upon stopping their medication, a situation that does not necessarily occur in everyday clinical practice. The study found that approximately 27% of patients transitioned to different medications, including older-generation obesity drugs. Additionally, 20% of participants eventually resumed their original medication once issues related to insurance or side effects were resolved. Furthermore, 14% of patients opted for intensive lifestyle modification programs, collaborating closely with dietitians and exercise specialists.
Researchers noted that patients who successfully maintained their weight tended to stay engaged with the healthcare system, whether through alternative prescriptions or structured lifestyle support. This ongoing engagement appears to play a crucial role in preventing significant weight regain.
Despite the promising findings, the study does have limitations. The authors acknowledged that the research included adult patients from a single large integrated health system in Ohio and Florida, which may affect the generalizability of the results. Variations in patient characteristics and healthcare delivery patterns across the United States could influence outcomes in different populations. Additionally, some of the observed weight reduction may be linked to other interventions that the researchers were unable to account for.
Looking ahead, Dr. Gasoyan expressed intentions to further investigate the comparative effectiveness of alternative treatment options for obesity in patients who discontinue semaglutide or tirzepatide. This future research aims to assist patients and their healthcare providers in making informed decisions regarding weight management strategies.
Overall, the Cleveland Clinic study offers a hopeful perspective for those considering the cessation of GLP-1 medications, suggesting that with appropriate support and alternative treatments, significant weight regain may not be an inevitable outcome.
According to Fox News, this research provides valuable insights into the real-world implications of stopping GLP-1 medications and underscores the importance of ongoing engagement with healthcare resources.